Evidence map›Paper›PMID 34292311›Full record

ArticleJAMA oncology2021

Assessment of Prostate Cancer Treatment Among Black and White Patients During the COVID-19 Pandemic.

Adrien N Bernstein, Ruchika Talwar, Elizabeth Handorf, Kaynaat Syed, John Danella, Serge Ginzburg, Laurence Belkoff, Adam C Reese, Jeffery Tomaszewski, Edouard Trabulsi and 8 more

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in JAMA oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.7field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 11 institutions in 1 country.

Adrien N BernsteinDivision of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Ruchika TalwarDivision of Urology, University of Pennsylvania, Philadelphia.
Elizabeth HandorfDepartment of Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Kaynaat SyedHealth Care Improvement Foundation, Philadelphia, Pennsylvania.
John DanellaDepartment of Urology, Geisinger Health System, Danville, Pennsylvania.
Serge GinzburgDepartment of Urology, Einstein Healthcare Network, Philadelphia, Pennsylvania.
Laurence BelkoffDivision of Urology, MidLantic Urology/Main Line Health, Bala Cynwyd, Pennsylvania.
Adam C ReeseDepartment of Urology, Temple University, Philadelphia, Pennsylvania.
Jeffery TomaszewskiDivision of Urology, Cooper University Health Care, Camden, New Jersey.
Edouard TrabulsiDepartment of Urology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Eric A SingerDivision of Urology, Rutgers Cancer Institute of New Jersey, New Brunswick.
Bruce JacobsDepartment of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Alexander KutikovDivision of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Robert UzzoDivision of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Jay D RamanDivision of Urology, Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania.
Thomas GuzzoDivision of Urology, University of Pennsylvania, Philadelphia.
Marc C SmaldoneDivision of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Andres CorreaDivision of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Fox Chase Cancer Center · USUniversity of Pennsylvania · USCooper University Health Care · USEinstein Healthcare Network · USGeisinger Health System · USMain Line Health · USPenn State Milton S. Hershey Medical Center · USRutgers Cancer Institute of New JerseyTemple University · USThomas Jefferson University · USUniversity of Pittsburgh · US

Funding

TUFCCC/HC Regional Comprehensive Cancer Health PartnershipU54CA221704 · NCI · HUNTER COLLEGE · PI Joel Erblich · 2018 to 2026
$10.6M
NCI NIH HHS U54 CA221704
6 · The paper itself

Abstract

Importance: Early in the COVID-19 pandemic, racial/ethnic minority communities disproportionately experienced poor outcomes; however, the association of the pandemic with prostate cancer (PCa) care is unknown. Objective: To assess the association between race and PCa care delivery for Black and White patients during the first wave of the COVID-19 pandemic. Design, Setting, and Participants: This multicenter, regional, collaborative, retrospective cohort study compared prostatectomy rates between Black and White patients with untreated nonmetastatic PCa during the COVID-19 pandemic (269 patients from March 16 to May 15, 2020) and prior (378 patients from March 11 to May 10, 2019). Main Outcomes and Measures: Prostatectomy rates. Results: Of the 647 men with nonmetastatic PCa, 172 (26.6%) were non-Hispanic Black men, and 475 (73.4%) were non-Hispanic White men. Black men were significantly less likely to undergo prostatectomy during the pandemic compared with White patients (1 of 76 [1.3%] vs 50 of 193 [25.9%]; P < .001), despite similar COVID-19 risk factors, biopsy Gleason grade groups, and comparable prostatectomy rates prior to the pandemic (17 of 96 [17.7%] vs 54 of 282 [19.1%]; P = .75). Black men had higher median prostate-specific antigen levels prior to biopsy (8.8 ng/mL [interquartile range, 5.3-15.2 ng/mL] vs 7.2 ng/mL [interquartile range, 5.1-11.1 ng/mL]; P = .04). A linear combination of regression coefficients with an interaction term for year demonstrated an odds ratio for likelihood of surgery of 0.06 (95% CI, 0.01-0.35; P = .002) for Black patients and 1.41 (95% CI, 0.81-2.44; P = .23) for White patients during the pandemic compared with prior to the pandemic. Changes in surgical volume varied by site (from a 33% increase to complete shutdown), with sites that experienced the largest reduction in cancer surgery caring for a greater proportion of Black patients. Conclusions and Relevance: In this large multi-institutional regional collaborative cohort study, the odds of PCa surgery were lower among Black patients compared with White patients during the initial wave of the COVID-19 pandemic. Although localized PCa does not require immediate treatment, the lessons from this study suggest systemic inequities within health care and are likely applicable across medical specialties. Public health efforts are needed to fully recognize the unintended consequence of diversion of cancer resources to the COVID-19 pandemic to develop balanced mitigation strategies as viral rates continue to fluctuate.

Indexed as

AgedAged, 80 and overBlack or African AmericanCOVID-19HumansMaleMiddle AgedNeoplasm GradingPandemicsProstatectomyProstatic NeoplasmsRetrospective StudiesUnited StatesWhite People

Identifiers

PMID34292311
PMCPMC8299356
OpenAlexW3186091646

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.